article thumbnail

Regional inequalities threatening Europe’s biosimilars market

European Pharmaceutical Review

The report noted that biosimilar adoption levels vary significantly across Europe because of differences in baseline use of biologics, biosimilar reimbursement, procurement, policies, and education, based on research published in a paper in the Journal of Market Access & Health Policy in 2017.

Marketing 110
article thumbnail

UK authority asks for director ban for Alliance Pharma CEO

pharmaphorum

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. Between 2013 and 2017, the price of a 50-tablet pack of prochlorperazine increased from £6.49 million to about £7.5 million, according to the CMA.

Pharma 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Oncology biosimilar case studies: rituximab biosimilars

Pharmaceutical Technology

The first approved biosimilar in the US and EU was Celltrion/Teva Pharmaceutical’s Truxima/Blitzima in 2018 and 2017, respectively. However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. In Japan, the first biosimilar was Pfizer’s Rituximab in 2019.

Sales 59
article thumbnail

Half a million-dollar bonus for cancer drug price increase

World of DTC Marketing

Porter then moved on to tear apart the $13 million Alles made in 2017 as Celgene’s CEO. This is a drug that has seen yearly price increases at a time when it’s facing more competition. ” Porter rhetorically responded, outlining how the average senior in her district couldn’t even afford one pill.

Pharma 181
article thumbnail

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

Impetus Digital

Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). Specific challenges facing the oncology field 1.

article thumbnail

Roche CEO Severin Schwan to stand down after 14 years

pharmaphorum

The appointment might raise some eyebrows given Roche’s need to drive pharma sales as it copes with the loss of patent protection on an earlier generation of antibody-based therapies – now being hit by biosimilar competition – but Schwan is confident Schinecker is the right man to lead the company forward.

Sales 114
article thumbnail

470% price increases

World of DTC Marketing

For a patient taking 3 tablets daily, the annual net price of Imbruvica increased from $72,587 in 2013 to $115,533 in 2017 (the last year for which AbbVie provided the Committee data). AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. net revenue from Humira.